Abbott Laboratories $ABT Shares Acquired by Commerzbank Aktiengesellschaft FI

Key Points

• Commerzbank Aktiengesellschaft FI increased its stake in Abbott Laboratories by 5.6% during the second quarter, owning 224,343 shares valued at approximately $30.5 million.
• Abbott Laboratories reported quarterly earnings of $1.26 per share, meeting analysts' expectations, with revenue of $11.14 billion, which exceeded predictions.
• The company announced a quarterly dividend of $0.59 per share to be paid on November 17th, representing an annualized yield of 1.8%.

Commerzbank Aktiengesellschaft FI raised its stake in Abbott Laboratories (NYSE:ABT - Free Report) by 5.6% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 224,343 shares of the healthcare product maker's stock after buying an additional 11,802 shares during the period. Commerzbank Aktiengesellschaft FI's holdings in Abbott Laboratories were worth $30,513,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of ABT. Hughes Financial Services LLC acquired a new position in shares of Abbott Laboratories in the 1st quarter worth $27,000. Abound Financial LLC acquired a new position in shares of Abbott Laboratories in the 1st quarter valued at $28,000. Elequin Capital LP purchased a new stake in Abbott Laboratories during the first quarter valued at about $30,000. JCIC Asset Management Inc. purchased a new stake in Abbott Laboratories during the first quarter valued at about $32,000. Finally, Vision Financial Markets LLC acquired a new stake in shares of Abbott Laboratories during the first quarter valued at approximately $33,000. Institutional investors own 75.18% of the company's stock.

Abbott Laboratories Trading Down 0.8%

NYSE:ABT opened at $133.24 on Friday. Abbott Laboratories has a 12 month low of $110.86 and a 12 month high of $141.23. The firm has a market cap of $231.90 billion, a price-to-earnings ratio of 16.70, a P/E/G ratio of 2.55 and a beta of 0.69. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25. The company's 50 day moving average is $132.44 and its 200-day moving average is $131.52.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its quarterly earnings data on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, hitting the consensus estimate of $1.26. The business had revenue of $11.14 billion during the quarter, compared to analysts' expectations of $11.01 billion. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The firm's revenue was up 7.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.14 EPS. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Equities analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 17th. Stockholders of record on Wednesday, October 15th will be paid a $0.59 dividend. The ex-dividend date is Wednesday, October 15th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.8%. Abbott Laboratories's dividend payout ratio is currently 29.57%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on ABT shares. Morgan Stanley boosted their price target on shares of Abbott Laboratories from $127.00 to $137.00 and gave the company an "equal weight" rating in a report on Tuesday, July 15th. Evercore ISI raised their target price on Abbott Laboratories from $140.00 to $144.00 and gave the stock an "outperform" rating in a research report on Tuesday. Royal Bank Of Canada raised their target price on Abbott Laboratories from $145.00 to $147.00 and gave the stock an "outperform" rating in a research report on Tuesday, July 15th. BTIG Research reduced their price objective on Abbott Laboratories from $148.00 to $145.00 and set a "buy" rating for the company in a research note on Friday, July 18th. Finally, Leerink Partners initiated coverage on Abbott Laboratories in a research note on Monday, June 16th. They issued a "market perform" rating and a $143.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Abbott Laboratories has a consensus rating of "Moderate Buy" and a consensus target price of $146.24.

Insider Activity

In other news, CFO Philip P. Boudreau sold 5,550 shares of the stock in a transaction on Friday, August 8th. The shares were sold at an average price of $134.55, for a total value of $746,752.50. Following the completion of the transaction, the chief financial officer owned 51,003 shares in the company, valued at approximately $6,862,453.65. This represents a 9.81% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.46% of the company's stock.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.